Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases.

Abstract

Highlights:  - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

• Authors: Ruth Webster, Adrianna Murphy, Helen Bygrave, Éimhín Ansbro, Diederick E Grobbee, Pablo Perel
• Journal: Global heart (Glob Heart) Vol. 15 Issue 1 Pg. 57 (08 19 2020) ISSN: 2211-8179 [Electronic] England
• PMID: 32923350 (Publication Type: Journal Article, Review)
• Copyright: Copyright: © 2020 The Author(s).

Chemical References

• Antihypertensive Agents
• Drug Combinations

Topics

• Antihypertensive Agents (administration & dosage)
• Cardiovascular Diseases (prevention & control)
• Dose-Response Relationship, Drug
• Drug Combinations
• Humans
• Secondary Prevention (methods)